Actively Recruiting
Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data
Led by AbbVie · Updated on 2026-04-16
2000
Participants Needed
2
Research Sites
13 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) in participants taking either prescribed or illicit drugs.
CONDITIONS
Official Title
Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Prescribed 8 weeks of Glecaprevir/Pibrentasvir (G/P)
- Treatment-nafve for the current infection
- Currently taking one or more prescription medications or illicit drugs
You will not qualify if you...
- Treated with direct-acting antivirals (DAAs) other than Glecaprevir/Pibrentasvir (G/P)
- History of decompensated cirrhosis
- History of Hepatitis B virus (HBV) infection
- History of hepatocellular carcinoma (HCC)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Vancouver Infectious Diseases Centre /ID# 275313
Vancouver, British Columbia, Canada, V6Z 2C7
Actively Recruiting
2
St. Clair Medical Clinic /ID# 275334
Toronto, Ontario, Canada, M4S 1Y2
Actively Recruiting
Research Team
D
Dimitri Semizarov
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here